This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
A Simple System to Identify Winning Stocks in Volatile Markets
by Bryan Hayes
Following a system rather than relying on predictions is going to produce much more favorable results over time.
If You Invested $1000 in Novo Nordisk a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Novo Nordisk (NVO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $166.02, marking a +0.62% move from the previous day.
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
by Zacks Equity Research
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.
AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
3 Top-Ranked Stocks Displaying Immense Relative Strength
by Derek Lewis
Stop me if you've heard this before, but stocks making new highs tend to make even higher highs, especially when analysts' positive earnings estimate revisions roll in.
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.
Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.
Beat the Market Like Zacks: NVIDIA, Clorox, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
by Zacks Equity Research
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Universal Health (UHS) to Release Q1 Earnings: Factors to Note
by Zacks Equity Research
Universal Health's (UHS) Q1 results are likely to benefit from higher patient volumes and solid demand for behavioral healthcare services. However, increased labor costs might partly offset the results.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.
The Zacks Analyst Blog Highlights Novo Nordisk, Salesforce, Comcast, Honeywell International and The Progressive
by Zacks Equity Research
Novo Nordisk, Salesforce, Comcast, Honeywell International and The Progressive are part of the Zacks top Analyst Blog.